Dr. Reddy’s Laboratories Announces Launch of India’s First DCGI-approved Semaglutide Injection ‘Obeda®’ for Type 2 Diabetes
The announcement marks Dr. Reddy’s Day‑1 entry into the GLP‑1 receptor agonists therapy space and readiness to serve patients in India In a head-to-head Phase-III...